Literature DB >> 21543973

Levodopa induces synthesis of nerve growth factor and growth hormone in patients with Parkinson disease.

Thomas Müller1, Reiner Hellwig, Siegfried Muhlack.   

Abstract

BACKGROUND: Polyneuropathy is observed in treated patients with Parkinson disease. Peripheral axonal degeneration is related to nerve growth factor metabolism. The causes for this axonal degeneration and the role of levodopa itself are not known. Levodopa may experimentally exert supportive effects on nerve growth factor synthesis and on growth hormone production, a hormonal compound with regenerative potential.
OBJECTIVE: The objective of this study was to investigate the effects of soluble 250-mg levodopa/benserazide administration on plasma occurrence of levodopa, nerve growth factor, and growth hormone in patients with Parkinson disease over an interval of 60 minutes.
RESULTS: Levodopa moderately increased bioavailability of nerve growth factor and growth hormone combined with the rise of levodopa. Nerve growth factor data and levodopa values correlated to each other.
CONCLUSIONS: Axonal degeneration may not be due to levodopa itself, as levodopa supports production of nerve growth factor and of growth hormone. Both may complement each other for neuronal survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543973     DOI: 10.1097/WNF.0b013e318219dad0

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

1.  Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia.

Authors:  Muhammad Asghar; Amani Odeh; Ahmad Jouni Fattahi; Alexandra Edwards Henriksson; Aurelie Miglar; Shervin Khosousi; Per Svenningsson
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 2.  l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.

Authors:  Yoshio Goshima; Daiki Masukawa; Yuka Kasahara; Tatsuo Hashimoto; Aderemi Caleb Aladeokin
Journal:  Front Pharmacol       Date:  2019-10-03       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.